Isavuconazole treatment of a patient with disseminated mucormycosis.

Abstract

We report a patient with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involving lung, brain, and skin. After failing posaconazole and being intolerant to amphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatment for relapsed leukemia.

• Authors: Driele Peixoto, Lisa S Gagne, Sarah P Hammond, Erin T Gilmore, Amy C Joyce, Robert J Soiffer, Francisco M Marty
• Journal: Journal of clinical microbiology (J Clin Microbiol) Vol. 52 Issue 3 Pg. 1016-9 (Mar 2014) ISSN: 1098-660X [Electronic] United States
• PMID: 24403304 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Nitriles
• Pyridines
• Triazoles
• isavuconazole

Topics

• Antifungal Agents (therapeutic use)
• Brain (microbiology, pathology)
• Humans
• Immunocompromised Host
• Leukemia, Myeloid, Acute (complications, therapy)
• Lung (microbiology, pathology)
• Male
• Middle Aged
• Mucormycosis (diagnosis, drug therapy, microbiology)
• Nitriles (therapeutic use)
• Pyridines (therapeutic use)
• Rhizomucor (isolation & purification)
• Skin (microbiology, pathology)
• Stem Cell Transplantation (adverse effects)
• Transplantation, Homologous (adverse effects)
• Treatment Outcome
• Triazoles (therapeutic use)